NCT01701349View on ClinicalTrials.gov

Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

December 31, 2017

Conditions
Anaplastic Thyroid Cancer
Interventions
DRUG

Fosbretabulin + paclitaxel + carboplatin

Fosbretabulin 200 mg/m2 IV infusion

DRUG

Placebo + paclitaxel + carboplatin

Paclitaxel 200 mg/m2, Carboplatin AUC 6 IV infusion

Sponsors
All Listed Sponsors
lead

Mateon Therapeutics

INDUSTRY